心脏病学中的生物标志物——第1部分——心力衰竭与特定心肌病
Biomarkers in cardiology--part 1--in heart failure and specific cardiomyopathies.
出版信息
Arq Bras Cardiol. 2014 Dec;103(6):451-9. doi: 10.5935/abc.20140184. Epub 2014 Nov 28.
Abstract
Cardiovascular diseases are the leading causes of mortality and morbidity in Brazil. The primary and secondary preventions of those diseases are a priority for the health system and require multiple approaches to increase their effectiveness. Biomarkers are tools used to more accurately identify high-risk individuals, to speed the diagnosis, and to aid in treatment and prognosis determination. This review aims to highlight the importance of biomarkers in clinical cardiology practice, and to raise relevant points of their use and the promises for the coming years. This document was divided into two parts, and this first one discusses the use of biomarkers in specific cardiomyopathies and heart failure.
摘要
心血管疾病是巴西死亡率和发病率的主要原因。这些疾病的一级和二级预防是卫生系统的优先事项，需要多种方法来提高其有效性。生物标志物是用于更准确地识别高危个体、加快诊断以及辅助治疗和预后判定的工具。本综述旨在强调生物标志物在临床心脏病学实践中的重要性，并提出其使用的相关要点以及未来几年的前景。本文分为两部分，第一部分讨论生物标志物在特定心肌病和心力衰竭中的应用。
相似文献
1
Biomarkers in cardiology--part 1--in heart failure and specific cardiomyopathies.
Arq Bras Cardiol. 2014 Dec;103(6):451-9. doi: 10.5935/abc.20140184. Epub 2014 Nov 28.
2
Biomarkers in Cardiology - Part 2: In Coronary Heart Disease, Valve Disease and Special Situations.
Arq Bras Cardiol. 2015 May;104(5):337-46. doi: 10.5935/abc.20150061. Epub 2015 May 1.
3
Current applications of biomarkers in cardiomyopathies.
Expert Rev Cardiovasc Ther. 2015;13(7):825-37. doi: 10.1586/14779072.2015.1053873.
4
New and emerging biomarkers of heart failure.
Crit Rev Clin Lab Sci. 2009;46(3):107-28. doi: 10.1080/10408360902722342.
5
Evaluation of patients with heart failure.
Cardiol Clin. 2014 Feb;32(1):47-62, viii. doi: 10.1016/j.ccl.2013.09.014.
6
Noncompaction cardiomyopathy presenting with congestive heart failure during intercurrent dengue viral illness: importance of phenotypic recognition.
Int J Cardiol. 2006 Feb 8;107(1):123-5. doi: 10.1016/j.ijcard.2005.01.064.
7
Cardiovascular genetic medicine: genomic assessment of prognosis and diagnosis in patients with cardiomyopathy and heart failure.
J Cardiovasc Transl Res. 2008 Sep;1(3):225-31. doi: 10.1007/s12265-008-9044-y. Epub 2008 Aug 2.
8
Cardiac troponin and heart failure in the era of high-sensitivity assays.
J Cardiol. 2012 Sep;60(3):160-7. doi: 10.1016/j.jjcc.2012.06.007. Epub 2012 Aug 4.
9
[Cardiomyopathies].
Versicherungsmedizin. 2002 Mar 1;54(1):3-10.
10
[Cardiomyopathies - heart failure: new concepts].
Dtsch Med Wochenschr. 2013 Mar;138(12):569. doi: 10.1055/s-0032-1332971. Epub 2013 Mar 12.
引用本文的文献
1
Long Non-Coding RNAs in Cardiovascular Diseases: Potential Function as Biomarkers and Therapeutic Targets of Exercise Training.
Noncoding RNA. 2021 Oct 11;7(4):65. doi: 10.3390/ncrna7040065.
2
Triggers of Inflammatory Heart Disease.
Front Cell Dev Biol. 2020 Mar 24;8:192. doi: 10.3389/fcell.2020.00192. eCollection 2020.
3
Risk stratification in hypertrophic cardiomyopathy.
Herz. 2020 Feb;45(1):50-64. doi: 10.1007/s00059-018-4700-8. Epub 2018 Apr 25.
4
Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure.
Arq Bras Cardiol. 2016 Feb;106(2):145-52. doi: 10.5935/abc.20150151. Epub 2016 Jan 15.
5
Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic Treatment.
Arq Bras Cardiol. 2016 Jan;106(1):62-9. doi: 10.5935/abc.20160005. Epub 2015 Dec 8.
本文引用的文献
1
Prognostic value of N-terminal pro-brain natriuretic Peptide in outpatients with hypertrophic cardiomyopathy.
Am J Cardiol. 2013 Oct 15;112(8):1190-6. doi: 10.1016/j.amjcard.2013.06.018. Epub 2013 Jul 19.
2
Plasma pro-B-type natriuretic peptide testing as a screening method for hypertrophic cardiomyopathy.
J Card Fail. 2012 Jul;18(7):564-8. doi: 10.1016/j.cardfail.2012.04.005. Epub 2012 May 19.
3
The role of micronutrients in heart failure.
J Acad Nutr Diet. 2012 Jun;112(6):870-86. doi: 10.1016/j.jand.2012.01.016.
4
Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
Am Heart J. 2012 May;163(5):821-8. doi: 10.1016/j.ahj.2012.03.004.
5
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
Am J Hematol. 2012 May;87(5):465-71. doi: 10.1002/ajh.23141. Epub 2012 Mar 3.
6
Exhaled acetone as a new biomaker of heart failure severity.
Chest. 2012 Aug;142(2):457-466. doi: 10.1378/chest.11-2892.
7
Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome.
Eur J Heart Fail. 2012 Apr;14(4):357-66. doi: 10.1093/eurjhf/hfr175. Epub 2012 Feb 3.
8
Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials.
Circulation. 2012 Jan 17;125(2):280-8. doi: 10.1161/CIRCULATIONAHA.111.044149. Epub 2011 Dec 2.
9
Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.
J Am Coll Cardiol. 2011 Oct 25;58(18):1881-9. doi: 10.1016/j.jacc.2011.03.072.
10
Cardiac magnetic resonance imaging pericardial late gadolinium enhancement and elevated inflammatory markers can predict the reversibility of constrictive pericarditis after antiinflammatory medical therapy: a pilot study.
Circulation. 2011 Oct 25;124(17):1830-7. doi: 10.1161/CIRCULATIONAHA.111.026070. Epub 2011 Oct 3.
Zotero 插件